Study: Dramatic rise in hepatitis C-related deaths in the United States

Hepatitis C virus (HCV) is the most common blood-borne infection in the United States, affecting about 1.3 percent of the population. Up to one-in-five sufferers develop liver cirrhosis, and up to one-in-20 develop liver cancer. HCV is the top reason for liver transplantation, and the 16th leading cause of premature death in the country. Recent evidence has suggested that disease burden and mortality from chronic HCV infection may increase in the coming years, as the number of persons with longstanding infections continues to rise.

To update estimates of trends and demographics of hepatitis C-related mortality in the U.S., a team of researchers led by Matthew Wise of UCLA and including researchers from the CDC and the Los Angeles County Department of Public Health analyzed mortality rates derived from U.S. Census and multiple-cause-of-death data from 1995-2004. They included 56,409 HCV related deaths, including those for which the disease was the underlying cause; those for which chronic liver disease was the underlying cause and hepatitis C was a contributing cause; and those for which HIV was the underlying cause and chronic liver disease and hepatitis C were contributing causes.

During the study period, HCV-related mortality rates increased from 1.09 deaths per 100,000 persons in 1995 to 2.57 per 100,000 in 2002, before declining slightly to 2.44 per 100,000 in 2004. Average annual increases were smaller during 2000-2004 than 1995-1999. The most dramatic age-specific increases were observed among 45 to 54 year olds who had an increase of 376 percent, and 55 to 64 year olds who had an increase of 188 percent. For the latter group, rates rose for the entire duration of the study.

“The highest mortality rates were observed among males, persons aged 45-54 and 55-64 years, Hispanics, non-Hispanic blacks and non-Hispanic Native American/Alaska Natives,” the authors report. They suggest that demographic differences are related to prevalence among the various populations.

The observed increases likely reflect both true increases in mortality and the growing use of serologic tests for HCV, the authors say. “As such, true increases in hepatitis C-related mortality during 1995-1999 were likely more gradual than the observed trends, and differences in mortality patterns between the time periods are difficult to interpret.” While the study was limited by possible inaccuracies in death certificate data, the authors believe that this more likely lead to an underestimate of the true number of hepatitis C-related deaths.

“In summary, substantial increases in overall hepatitis-C-related mortality rates have occurred since 1995,” the authors conclude. “The relatively young age of persons dying from hepatitis C-related liver disease has made hepatitis C-related disease a leading infectious cause of years of potential life lost as well as an important cause of premature mortality overall.” They point out the ongoing need for measures to prevent progression of liver disease among those infected with HCV, and the need for ongoing analysis of mortality trends.

Source: Blackwell Publishing

Elevated liver enzymes associated with higher future mortality
A new population-based epidemiological study has found that elevated liver enzymes discovered during routine medical care are associated with higher future mortality. The findings are in the March issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).
Safe water? Lessons from Kazakhstan
Despite significant efforts to improve access to safe water and sanitation, a new report co-authored by an expert at The University of Nottingham, argues that much more needs to be done.
Combining liver cancer treatments doubles survival rates, researchers find
By combining the use of stents and photodynamic therapy, also called SpyGlass, physicians at the University of Virginia have been able to significantly increase survival rates for patients suffering from advanced cholangiocarcinoma, cancer of the liver bile duct.
Sunitinib may slow growth and spread of liver cancer
Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver, researchers report.
Researchers pilot new electronic system for infectious illness
Researchers at Harvard Pilgrim Health Care, Harvard Medical School, Atrius Health, and the Massachusetts Department of Public Health have created and tested a set of computer programs that use electronic medical records to help clinicians detect contagious illness and automatically report them to public health departments.
Potential drug target identified for diabetes by studying novel gut-brain-liver circuit
Scientists at the Toronto General Hospital Research Institute have discovered a novel signaling pathway between three organs – the gut, the brain, and the liver – which lowers blood sugar when activated.
Tart cherries may reduce factors associated with heart disease and diabetes
Tart cherries – frequently sold dried, frozen or in juice – may have more than just good taste and bright red color going for them, according to new animal research from the University of Michigan Cardiovascular Center.
New Parasite Discovered; Infects Waterfowl, Other Species
Microbiologists at Oregon State University have discovered a new species of “myxozoan” parasite that has been found for the first time to infect a warm blooded animal – in this case, ducks - after evolving from its relatives that are common in cold-blooded fish and aquatic worms.

Study: Dramatic rise in hepatitis C-related deaths in the United States

Related stories:

News discussion: